RNA Interference Myopia Treatment via PAX-6 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective treatments and risk assessments for myopia, with no established role of microRNAs in myopia development or use of RNA interference for its prevention or treatment.
Innovation Solution
Administering RNA interference, specifically microRNA-328, to inhibit PAX-6 gene expression, which is associated with myopia development, to treat and prevent myopia, and assess risk through RNA interference-based methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNA interference (microRNA-328) is administered to inhibit PAX-6 gene expression, then myopia treatment and prevention effectiveness is improved, but the complexity of the treatment method increases
Solution Approach 1:
The patent uses RNA interference molecules (specifically anti-miR-328) as intermediaries to block the harmful interaction between miR-328 and PAX-6 mRNA. This intermediary approach allows treatment without directly modifying the PAX-6 gene or requiring complex surgical interventions, thereby improving treatment effectiveness while maintaining relative simplicity
Solution Approach 2:
The patent changes the molecular parameter by introducing exogenous RNA molecules that specifically bind to and inhibit endogenous microRNA-328. This parameter change at the molecular level achieves precise control over PAX-6 expression, improving treatment reliability through targeted molecular intervention
2Measurement precision
If RNA interference is used to assess myopia risk, then diagnostic precision is improved, but the difficulty of detection and measurement increases
Solution Approach 1:
The patent replaces traditional mechanical or physical diagnostic methods with molecular biology-based RNA interference assays. This substitution enables detection at the molecular level, providing higher diagnostic precision for myopia risk assessment through measurement of miR-328 and PAX-6 interactions
Solution Approach 2:
The patent uses RNA molecules as copies or proxies to detect the functional state of the PAX-6 gene pathway. By measuring RNA interference activity rather than directly measuring phenotypic outcomes, the system achieves higher precision in risk assessment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces PAX-6 expression, influencing retinal and scleral cell proliferation and gene expression, providing a method for treating and preventing myopia and assessing risk.
Implementation Method 1
Micro RNAs are capable of regulating cell growth, differentiation, and apoptosis... The annealing of a micro RNA to its target messenger RNA causes an inhibition of protein translation, and/or cleavage of the messenger RNA
Data Source
AI summary
The present disclosure provides a method for treating and/or preventing myopia, including: administering an RNA interference (RNAi) to a subject, wherein the RNA interference is capable of counteracting another RNA interference, and the other RNA interference is an RNA interference capable of inhibiting an expression of PAX-6 gene, and the RNA interference capable of inhibiting an expression of PAX-6 gene comprises microRNA-328.